Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3299526 | 0.99 | ACHE (0.45) | ACHEFAAHDRD4HTR4CYP2D6 | |
| SCHEMBL3299250 | 0.95 | HTR4 (0.44) | ACHEFAAHDRD4HTR4 | |
| SCHEMBL3299143 | 0.93 | FAAH (0.46) | ACHEFAAHDRD4HTR4CYP2D6 | |
| SCHEMBL3301369 | 0.93 | HTR4 (0.42) | ACHEFAAHHTR4CYP2D6 | |
| SCHEMBL3297520 | 0.91 | USP2 (0.41) | ACHEFAAHHTR4ALDH1A1SCN1A | |
| SCHEMBL3301226 | 0.91 | FAAH (0.45) | ACHEFAAHDRD4HTR4CYP2D6 | |
| SCHEMBL3303349 | 0.91 | HTR4 (0.54) | ACHEFAAHDRD4HTR4 | |
| SCHEMBL2333287 | 0.88 | DRD4 (0.55) | ACHEFAAHDRD4CYP2D6ALDH1A1 | |
| SCHEMBL3304360 | 0.85 | HTR4 (0.43) | ACHEFAAHDRD4HTR4 | |
| SCHEMBL15103639 | 0.85 | HTR4 (0.58) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676718-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-06-13 | — | — | US | claimed |
| US-9593102-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-14 | — | — | US | claimed |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-12-15 | — | — | US | claimed |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-15 | — | — | US | claimed |
| EP-2358702-B1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-07-17 | — | — | EP | claimed |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-12-04 | — | — | US | disclosed |
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-09-28 | — | — | US | disclosed |
| US-9676718-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9593102-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-12-15 | — | — | US | disclosed |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-15 | — | — | US | disclosed |
| US-8642772-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-02-04 | — | — | US | disclosed |
| US-20100093801-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK HOLDINGS CO., LTD. (KR) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | ACHE 772/4885FAAH 849/4885DRD4 317/4885 |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | PGC, VIP, PIGO | ACHE 772/4885FAAH 849/4885DRD4 317/4885 |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | PGC, VIP, PIGO | ACHE 772/4885FAAH 849/4885DRD4 317/4885 |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | ACHE 772/4885FAAH 849/4885DRD4 317/4885 |
| US-20100093801-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | ACHE 772/4885FAAH 849/4885DRD4 317/4885 |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | ACHE 772/4885FAAH 849/4885DRD4 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.